

Work-related dysphonia in subjects with occupational asthma is associated with neutrophilic airway inflammation

To the editor,

Vertigan et al.¹ recently highlighted the comorbid association between asthma and laryngeal dysfunction, although the pathophysiological mechanisms underlying this complex association remain largely uncertain.² It is widely acknowledged that laryngeal dysfunction, including vocal cord dysfunction, can be triggered by external stimuli, such as exercise, strong odors and irritant exposures.² In this regard, workplace exposure to respiratory irritants has been reported as an important cause of the “work-related irritable larynx syndrome”.³

We sought to assess the clinical characteristics and airway inflammatory processes associated with work-related dysphonia in a cohort of subjects with sensitizer-induced occupational asthma (OA) ascertained by a positive specific inhalation challenge (SIC). This retrospective study included 341 subjects identified among the multicenter European network for the PHenotyping of Occupational Asthma (E-PHOCAS)⁴ who met the following eligibility criteria: (1) complete information on variables addressing asthma severity and control while exposed at work; (2) available information on self-reported dysphonia (i.e. hoarseness or loss of voice) at work; and (3) assessment of induced sputum cell counts at the time of the SIC procedure.

Forty-nine (14.4%) subjects experienced dysphonia while exposed at their workplace. The baseline clinical features and sputum cell counts of the subjects with and without dysphonia as well as the univariate associations with dysphonia are detailed in Table 1. A multivariable logistic regression analysis was conducted in order to identify the clinical and inflammatory characteristics that were associated with work-related dysphonia. The independent variables incorporated into these regression models included gender; sinusitis; high-level treatment at work (i.e., Global Initiative for Asthma treatment step four-fifths); poor asthma control at work (i.e., need for an inhaled short-acting β_2 -agonist once or more a day); OA caused by a low- versus a high-molecular-weight agent; as

well as eosinophil and neutrophil sputum cell counts (expressed as % of total nonsquamous cells; Table 2). The multivariate logistic regression analysis revealed that female gender (odds ratio [OR], 2.04; 95% confidence interval [CI], 1.06–3.92; $p = 0.031$) and a higher sputum neutrophil count (OR for each 5%-increase in neutrophil count, 1.09; 95% CI, 1.01–1.18; $p = 0.025$) were significantly associated with a higher likelihood of work-related dysphonia (Table 2). There was an association of borderline significance between dysphonia and high-level treatment (OR, 1.97; 95% CI, 0.97–3.95; $p = 0.057$). Dysphonia showed a negative association with increased sputum eosinophil counts (OR, 0.41; 95% CI, 0.19–0.83; $p = 0.017$).

Dysphonia is a main symptom of worked-associated irritable larynx syndrome (WILS) which has been defined as neuronal sensitization by a workplace trigger bringing about laryngeal dysfunction.³ As recently described, neutrophil inflammation can regulate sensory neuron function, especially in chronic pain.⁵

To our knowledge, our study is the first to describe a relationship between neutrophilic inflammation and work related dysphonia.

We acknowledge the limitations inherent to the retrospective cross-sectional design of this study. The presence of dysphonia was not objectively documented through direct visualization of inappropriate laryngeal movement. In addition, dysphonia was not assessed during the SIC procedure implying that it was not possible to ascertain that the agent inducing the positive SIC response was also the cause of dysphonia at work.

Despite their inherent limitations, our findings suggest that airway neutrophilic inflammation could be involved in the development of work-related laryngeal dysfunction. This study highlights the need for further prospective studies using validated questionnaires, laryngoscopy, and induced sputum analysis in order to explore the association between laryngeal dysfunction and neutrophilic airway inflammation.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

TABLE 1 Univariate associations with self-reported dysphonia at work

Characteristics	Missing values	Subjects without dysphonia at work (n = 292)	Subjects with dysphonia at work (n = 49)	OR (95% CI)	p value
Age, year ^a	0	43 (34–51)	42 (38–52)	1.02 (0.99–1.05)	0.279
Sex, female	0	97 (33.2)	23 (46.9)	1.78 (0.96–3.28)	0.065
Body mass index ≥ 30 kg/m ^{2a}	0	82 (28.1)	15 (30.6)	1.13 (0.57–2.15)	0.717
Ex-smokers	0	83 (28.4)	10 (20.4)	0.66 (0.29–1.38)	0.286
Current smokers	0	62 (21.2)	12 (24.5)	1.05 (0.49–2.17)	0.890
Atopy ^b	4/0	146 (50.7)	28 (57.1)	1.30 (0.71–2.41)	0.405
Chronic rhinosinusitis	2/0	21 (7.2)	8 (16.3)	2.50 (0.99–5.83)	0.041
Exposure before symptom onset, months ^a	2/0	108 (48–204)	150 (21–230)	1.00 (1.00–1.00)	0.218
Duration of asthma symptoms at work, months ^a	3/0	36 (16–84)	33 (21–68)	1.00 (0.99–1.00)	0.522
Type of causal agent, LMW	0	191 (65.4)	25 (51.0)	1.81 (0.98–3.33)	0.057
Asthma treatment at work					
Daily dose of ICS, $\mu\text{g}^{\text{a,c}}$	0	500 (0–1000)	500 (0–1000)	1.00 (1.00–1.00)	0.827
High level treatment ^d	0	19 (6.5)	6 (12.2)	2.12 (1.14–3.94)	0.017
Poor asthma control while at work ^e	0	74 (25.3)	21 (42.9)	2.21 (1.17–4.11)	0.013
≥ 2 exacerbations last 12 months at work	0	26 (8.9)	1 (2.0)	0.21 (0.01–1.04)	0.134
Baseline spirometry					
FVC, % pred ^a	0	101 (90–110)	103 (94–110)	1.01 (0.99–1.03)	0.610
FEV ₁ , % pred ^a	0	90 (79–98)	91 (78–98)	1.01 (0.98–1.03)	0.602
FEV ₁ /FVC, % ^a	0	74 (67–80)	75 (67–78)	1.00 (0.97–1.03)	0.981
Airflow obstruction ^f	0	56 (19.2)	13 (26.5)	1.52 (0.73–3.00)	0.238
Baseline NSBH					
Absent	22/0	56 (20.7)	11 (22.4)	1.11 (0.51–2.24)	0.787
Mild		139 (51.5)	27 (55.1)	1.16 (0.63–2.15)	0.641
Moderate/severe		75 (27.8)	11 (22.4)	0.75 (0.35–1.50)	0.440
Blood eosinophils, cells/ μl^{a}	58/10	280 (199–400)	249 (140–390)	1.00 (1.00–1.00)	0.335
Baseline FeNO, ppb ^a					
	184/10	22 (12–41)	22 (10–28)	0.98 (0.96–1.00)	0.049
Baseline sputum eosinophils					
% ^a	0	2.0 (1.0–6.0)	1.2 (0.2–2.5)	0.87 (0.77–0.95)	0.011
$\geq 3\%$		125 (42.8)	12 (24.5)	0.43 (0.21–0.84)	0.018
Baseline sputum neutrophils					
% ^a	0	51.0 (36.0–70.0)	60.0 (48.2–78.5)	1.02 (1.00–1.03)	0.017
$\geq 76\%$		57 (19.5)	15 (30.6)	1.82 (0.91–3.52)	0.081

Note: Data are presented as n (% of available data) unless otherwise specified. Bold indicates variable with univariate association demonstrating a p value under 0.1.

Abbreviations: FeNO, fractional exhaled nitric oxide; FEV₁, forced expiratory volume in one-second; FVC, forced vital capacity; ICS, inhaled corticosteroid; LMW, low-molecular-weight; NSBH, nonspecific bronchial hyperresponsiveness; SIC, specific inhalation challenge.

^aMedian value with interquartile range (IQR) within parentheses.

^bAtopy defined by the presence of at least one positive skin prick test result to common allergens.

^cDaily dose of inhaled corticosteroid expressed as beclomethasone dipropionate equivalent.

^dHigh-level treatment defined as treatment step 4 or 5 of the Global Initiative for Asthma (<http://www.ginasthma.org>).

^ePoor asthma control at work is defined as the use of SABA more than once a day.

^fAirflow obstruction defined by an FEV₁ <80% predicted and an FEV₁/FVC ratio <70%.

TABLE 2 Logistic multivariate model for dysphonia at work

Independent variables	Dysphonia at work (n = 49/341)		
	OR	(95% CI)	p value
Sex, female	2.04	(1.06–3.92)	0.031
Chronic rhinosinusitis			
Poor asthma control while at work ^a	1.84	(0.91–3.71)	0.087
Type of causal agent, LMW			
High level treatment ^b	1.97	(0.97–3.95)	0.057
Eosinophil sputum cell counts $\geq 3\%$	0.41	(0.19–0.83)	0.017
Neutrophil sputum cell counts, 5% increase	1.05	(1.03–1.07)	<0.001

Note: The model included 338 patients, selection of variables was realized by a stepwise procedure based on Akaike information criterion. Bold indicates variable associated with a statistical significance, demonstrating a p value under 0.05.

Abbreviation: LMW, low-molecular-weight.

^aPoor asthma control at work is defined as the use of SABA more than once a day.

^bHigh-level treatment defined according to GINA as treatment step 4 or 5.

AUTHOR CONTRIBUTIONS

All E-PHOCAS investigators contributed to the conception and design of the study. All authors contributed to the acquisition, analysis and interpretation of the data. They provided input into the drafting of the manuscript, critical feedback, and final approval for submission of the manuscript for publication. NM is the guarantor of the final content of the manuscript.

KEYWORDS

dysphonia, neutrophilic inflammation, occupational asthma

ACKNOWLEDGMENTS

Olivier Vandenplas was supported in part by a grant from the *Fondation Mont-Godinne*. Frédéric de Blay and Nicolas Miguères were supported by a grant from the *Association d'Aide aux Insuffisants Respiratoires d'Alsace (ADIRAL)*.

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare.

FUNDING INFORMATION

Association d'Aide aux Insuffisants Respiratoires d'Alsace (ADIRAL); Fondation Mont-Godinne

Nicolas Miguères^{1,2} 
 Olivier Vandenplas³
 Jolanta Walusiak-Skorupa⁴
 Xavier Munoz⁵
 Hille Suojalehto⁶
 Vera van Kampen⁷ 
 Paola Mason⁸
 Santiago Quirce⁹
 Frédéric de Blay¹

on behalf of the European network for the PHenotyping of Occupational Asthma (E-PHOCAS)

¹Department of Chest Diseases, Division of Pulmonology, University Hospital of Strasbourg and Fédération de Médecine translationnelle, Strasbourg University, Strasbourg, France

²UMR 7357 Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie ICUBE, Strasbourg, France

³Service de Pneumologie, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium

⁴Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland

⁵Servei Pneumologia, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona and CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain

⁶Occupational Health, Finnish Institute of Occupational Health, Helsinki, Finland

⁷Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University, Bochum, Germany

⁸Department of Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy

⁹Department of Allergy, La Paz University Hospital, IdiPAZ and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain

Correspondence

Nicolas Miguères, Department of Chest Diseases, Division of Pulmonology, University Hospital of Strasbourg and Fédération de Médecine translationnelle, Strasbourg University, Strasbourg, France.

Email: nicolas.miguères@chru-strasbourg.fr

DATA AVAILABILITY STATEMENT

Research data are not shared.

ORCID

Nicolas Miguères  <https://orcid.org/0000-0002-3923-8505>

Vera van Kampen  <https://orcid.org/0000-0002-5694-4663>

REFERENCES

1. Vertigan AE, Kapela SL, Gibson PG. Laryngeal dysfunction in severe asthma: a cross-sectional observational study. *J Allergy Clin Immunol Pract.* 2021;9(2):897-905. <https://doi.org/10.1016/j.jaip.2020.09.034>
2. Lee J-H, An J, Won H-K, et al. Prevalence and impact of comorbid laryngeal dysfunction in asthma: a systematic review and meta-analysis. *J Allergy Clin Immunol.* 2020;145(4):1165-1173. <https://doi.org/10.1016/j.jaci.2019.12.906>
3. Denton E, Hoy R. Occupational aspects of irritable larynx syndrome. *Curr Opin Allergy Clin Immunol.* 2020;20(2):90-95. <https://doi.org/10.1097/aci.0000000000000619>
4. Vandenplas O, Godet J, Hurdubaea L, et al. Severe occupational asthma: insights from a multicenter European cohort. *J Allergy Clin Immunol Pract.* 2019;7:2309-2318.e4. <https://doi.org/10.1016/j.jaip.2019.03.017>
5. Kanashiro A, Hiroki CH, da Fonseca DM, et al. The role of neutrophils in neuro-immune modulation. *Pharmacol Res.* 2020;151:104580. <https://doi.org/10.1016/j.phrs.2019.104580>

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.